Reviva Pharmaceuticals Holdings, Inc. Financing Cash Flow
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Financing Cash Flow of $11.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$184.87K, a 101.83% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $11.55M, a 158787.84% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $7.05M, a 58.55% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $8.41M, a 132.16% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $25.56M, a 8.05% increase from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $23.65M, a 28.70% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $33.17M, a 325.69% increase from fiscal 2022.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $7.79M, a 75.34% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 2 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 5 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 8 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 11 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$184.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $11.37M 10-Q · filed 2026-08-12 | $18.42M derived: sum of 3 quarters · filed 2026-08-12 | $26.83M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2026-03-31 | $11.55M 10-Q · filed 2026-05-13 | $18.61M derived: sum of 2 quarters · filed 2026-05-13 | $27.02M derived: sum of 3 quarters · filed 2026-05-13 | $37.10M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-12-31 | $7.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $15.46M derived: sum of 2 quarters · filed 2026-03-30 | $25.55M derived: sum of 3 quarters · filed 2026-08-12 | $25.56M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | $8.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $18.50M derived: sum of 2 quarters · filed 2026-08-12 | $18.50M 10-Q · filed 2025-11-13 | $35.52M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-06-30 | $10.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $10.09M 10-Q · filed 2026-08-12 | $27.11M derived: sum of 3 quarters · filed 2026-08-12 | $30.73M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-03-31 | $7.27K 10-Q · filed 2026-05-13 | $17.03M derived: sum of 2 quarters · filed 2026-05-13 | $20.65M derived: sum of 3 quarters · filed 2026-05-13 | $23.33M derived: sum of 4 quarters · filed 2026-05-13 | |||||
| 2024-12-31 | $17.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $20.64M derived: sum of 2 quarters · filed 2026-03-30 | $23.32M derived: sum of 3 quarters · filed 2026-03-30 | $23.65M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $3.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.30M derived: sum of 2 quarters · filed 2025-11-13 | $6.63M 10-Q · filed 2025-11-13 | $33.91M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $3.01M 10-Q · filed 2025-08-14 | $30.28M derived: sum of 3 quarters · filed 2025-08-14 | $30.28M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | $332.00K 10-Q · filed 2025-05-15 | $27.60M derived: sum of 2 quarters · filed 2025-05-15 | $27.60M derived: sum of 3 quarters · filed 2025-05-15 | $32.82M derived: sum of 4 quarters · filed 2025-05-15 | |||||
| 2023-12-31 | $27.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $27.27M derived: sum of 2 quarters · filed 2025-04-03 | $32.48M derived: sum of 3 quarters · filed 2025-04-03 | $33.17M 10-K · filed 2025-04-03 | |||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $5.21M derived: sum of 2 quarters · filed 2024-11-14 | $5.90M 10-Q · filed 2024-11-14 | $5.92M derived: sum of 4 quarters · filed 2024-11-14 | |||||
| 2023-06-30 | $5.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $5.90M 10-Q · filed 2024-08-14 | $5.92M derived: sum of 3 quarters · filed 2024-08-14 | $13.69M derived: sum of 4 quarters · filed 2024-08-14 | |||||
| 2023-03-31 | $687.09K 10-Q · filed 2024-05-14 | $705.66K derived: sum of 2 quarters · filed 2024-05-14 | $8.48M derived: sum of 3 quarters · filed 2024-05-14 | $8.48M derived: sum of 4 quarters · filed 2024-05-14 | |||||
| 2022-12-31 | $18.56K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $7.79M derived: sum of 2 quarters · filed 2024-04-15 | $7.79M derived: sum of 3 quarters · filed 2024-04-15 | $7.79M 10-K · filed 2024-04-15 | |||||
| 2022-09-30 | $7.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $7.77M derived: sum of 2 quarters · filed 2023-11-14 | $7.77M 10-Q · filed 2023-11-14 | $7.87M derived: sum of 4 quarters · filed 2023-11-14 | |||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $70.00 10-Q · filed 2023-08-14 | $98.55K derived: sum of 3 quarters · filed 2023-08-14 | $98.55K derived: sum of 4 quarters · filed 2023-08-14 | |||||
| 2022-03-31 | $70.00 10-Q · filed 2023-05-15 | $98.55K derived: sum of 2 quarters · filed 2023-05-15 | $98.55K derived: sum of 3 quarters · filed 2023-05-15 | $31.60M derived: sum of 4 quarters · filed 2023-05-15 | |||||
| 2021-12-31 | $98.48K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $98.48K derived: sum of 2 quarters · filed 2023-03-30 | $31.60M derived: sum of 3 quarters · filed 2023-03-30 | $31.60M 10-K · filed 2023-03-30 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $31.50M derived: sum of 2 quarters · filed 2022-11-14 | $31.50M 10-Q · filed 2022-11-14 | $42.84M derived: sum of 4 quarters · filed 2022-11-14 | |||||
| 2021-06-30 | $31.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $31.50M 10-Q · filed 2022-08-15 | $42.84M derived: sum of 3 quarters · filed 2022-08-15 | ||||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | $11.34M derived: sum of 2 quarters · filed 2022-05-16 | |||||||
| 2020-12-31 | $11.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $12.83M 10-K · filed 2022-03-15 | $12.49M 10-K · filed 2021-03-22 | ||||||
| 2020-11-30 | $440.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14 | -$25.87M 10-Q · filed 2021-01-14 | |||||||
| 2020-09-30 | $874.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.48M 10-Q · filed 2021-11-15 | |||||||
| 2020-08-31 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-10-14 | -$26.31M 10-Q · filed 2020-10-14 | |||||||
| 2020-06-30 | $380.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $610.00K 10-Q · filed 2021-08-16 | |||||||
| 2020-05-31 | -$26.61M 10-Q · filed 2020-07-07 | ||||||||
| 2020-03-31 | $230.00K 10-Q · filed 2021-05-17 | ||||||||
| 2020-02-29 | -$5.52M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-04 | -$5.52M derived: sum of 2 quarters · filed 2021-01-14 | -$5.52M derived: sum of 3 quarters · filed 2021-01-14 | -$5.52M 10-K · filed 2020-05-04 | |||||
| 2019-12-31 | $100.00K 10-K/A · filed 2021-05-07 | ||||||||
| 2019-11-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14 | $0.00 derived: sum of 2 quarters · filed 2021-01-14 | $0.00 10-Q · filed 2021-01-14 | ||||||
| 2019-08-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-10-14 | $0.00 10-Q · filed 2020-10-14 | |||||||
| 2019-05-31 | $0.00 10-Q · filed 2020-07-07 | ||||||||
| 2019-02-28 | $65.05M 10-K · filed 2020-05-04 | ||||||||
| 2018-11-30 | $65.05M 10-Q · filed 2020-01-10 | ||||||||
| 2018-08-31 | $65.05M 10-Q · filed 2019-10-08 | ||||||||
| 2018-05-31 | $18.34K 10-Q · filed 2019-07-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |